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Interleukin-18 (IL-18) is a highly regulated inflammatory cytokine that is elevated in synovial tissues and
synovial fluids of patients with rheumatoid arthritis (RA) compared with patients with osteoarthritis (OA) and
patients with other arthropathies. Within the RA joint, IL-18 can contribute to the inflammatory process by
inducing leukocyte extravasation through upregulation of endothelial cell adhesion molecules, the release of
chemokines from RA synovial fibroblasts, and directly as a monocytes, lymphocyte, and neutrophil chemoat-
tractant. IL-18 can also help maintain and develop the inflammatory pannus by inducing endothelial cell
migration and angiogenesis. IL-18 does this directly by binding and activating endothelial cells and indirectly by
inducing RA synovial fibroblasts to produce angiogenic chemokines and vascular endothelial growth factor. IL-
18 is present in RA synovial fluid in high levels, where it functions as an angiogenic mediator and leukocyte
chemoattractant. IL-18 mediates all these inflammatory processes by binding to its receptor, IL-18 receptor, and
initiating the activation of different signaling cascades leading to changes in target cells gene expression and
behavior. IL-18 has been identified as a potential therapeutic target in the treatment of RA.
Interleukin-18
Interleukin-18 (IL-18), a member of the IL-1 superfamily,is produced as an inactive 23-kDa protein that is cleaved
by intracellular protease caspase-1, resulting in a biologically
active, mature 18-kDa protein that is then secreted in an ATP-
dependent manner via the purinergic receptor, purinergic re-
ceptor P2X7 (P2X7) (Mehta and others 2001). IL-18 has diverse
functions and can induce T cell adhesion and chemotaxis as
well as promote T helper cells to differentiate into either T
helper 1 (Th1) or Th2 cells depending upon which other cy-
tokines are present (Nakanishi and others 2001; Ariel and
others 2002; Komai-Koma and others 2003; Dai and others
2007). Additionally, IL-18 can augment the innate immune
response by increasing natural killer (NK) cell cytotoxicity,
increasing NK cell interferon-g (IFN-g) production, directly
and indirectly inducing monocyte chemotaxis, indirectly in-
ducing neutrophil chemotaxis, and increasing monocyte acti-
vation. IL-18 functions by binding to its heterodimeric
receptor on the surface of the target cell. This receptor consists
of an IL-18-binding a chain and a non-IL-18-binding b chain
that is responsible for signal transduction.
IL-18 Binding Protein
IL-18 binding protein (IL-18BP) is a constitutively ex-
pressed high affinity receptor for IL-18 (Novick and others
1999). There are 4 different human isoforms of IL-18BP(a-d)
created by alternate splicing with isoforms a and c capable of
binding IL-18 (Kim and others 2000). IL-18BPa is the major
splice variant and has the strongest binding affinity of the
isoforms. The primary activator of IL-18BP production is IFN-g
and as such creates a negative feedback loop controlling IL-18
levels in which IL-18-induced IFN-g results in increased IL-
18BP and reduced IL-18 levels (Moller and others 2003).
IL-18 Regulation
IL-18 biologic activity is highly regulated by several different
mechanisms. First, it must be expressed, and then it has to be
cleaved releasing the biologically active portion. Caspase-1, the
primary enzyme responsible for pro-IL-18 cleavage to its active
mature form, is also highly regulated. However, other non-
caspase-1 mechanisms can generate biologically active IL-18,
including proteinase 3 cleavage (Sugawara and others 2001).
Once released, IL-18 can be bound by either IL-18BP or soluble
IL-18 receptor (IL-18R), preventing its biologic activity. If active
IL-18 circumvents these regulatory mechanisms, its activity is
still mediated by other cytokines with which it functions in
synergy, such as IL-12 and IL-15 (Yamamura and others 2001;
Gracie and others 2003). Additionally, expression of the IL-18R
determines the cell type that will respond to IL-18. Finally, the
signaling pathways will determine the activation of the cells
both producing the IL-18 and being stimulated by IL-18.
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Ultimately, the biologic activity of IL-18 is not only determined
by the production of IL-18 but also the production of other
molecules, including caspase-1, IL-18BP, soluble IL-18R, IL-12,
IL-15, IL-18R, and several signaling cascades.
IL-18’s Role in Rheumatoid Arthritis
In rheumatoid arthritis (RA), IL-18 is significantly elevated
in sera, synovial tissues, and synovial fluid compared with
those from osteoarthritic patients and patients with other
arthropathies (Gracie and others 1999; Yamamura and others
2001; Bresnihan and others 2002). IL-18 levels correlate with
acute phase proteins and disease activity (Yamamura and
others 2001; Petrovic-Rackov and Pejnovic 2006; Shao and
others 2009). In the RA joint, IL-18 is primarily produced by
synovial lining macrophages; however, it is also produced by
synovial fibroblasts, endothelial cells, dendritic cells, articu-
lar chondrocytes, osteoblasts, and synovial fluid neutrophils
(Gracie and others 1999; Moller and others 2002; Verri and
others 2007). In vitro, IL-18 is expressed by CD68 + macro-
phages, neutrophils, and RA synovial fibroblasts. Ad-
ditionally, IL-18 expression can be induced by cytokine
stimulation of RA synovial fibroblasts and RA peripheral
blood neutrophils (Gracie and others 1999; Verri and others
2007). While there have been reports that RA synovial fi-
broblasts produce IL-18 mRNA but do not make mature
biologically active IL-18 (Yamamura and others 2001; Zeisel
and others 2004), we recently reported that RA synovial fi-
broblasts release biologically active IL-18 (Marotte and oth-
ers 2010). Specifically, tumor necrosis factor-a (TNF-a)
stimulation of RA synovial fibroblasts results in IL-18 ex-
pression and production of biologically active IL-18. This
activation of RA synovial fibroblasts by TNF-a is dependent
upon the activation of the extracellular signal-regulated
kinase 1/2 (ERK1/2) signaling pathway. Based upon their
production in the RA joint, there is potentially a positive
feedback loop between IL-18-producing synovial fibroblasts
and TNF-a-producing, synovial macrophages, which could
result in the escalation of inflammation seen in RA.
IL-18 stimulates synovial lymphocytes, macrophages, and
fibroblasts through binding to the IL-18Rs on the surface of
these cells (Gracie and others 2003). While there is some con-
tention as to whether synovial fibroblasts produce both a and b
chains of the IL-18R (Kawashima and Miossec 2003) and
whether they respond to IL-18 stimulation (Moller and others
2002), we and others have shown RA synovial fibroblasts to
respond directly to IL-18 stimulation resulting in the activation
of signaling cascades and the initiation of the expression of
cytokines, adhesion molecules, and angiogenic mediators
(Morel and others 2001a, 2001b, 2002; Ruth and others 2003;
Cho and others 2006; Amin and others 2007). Specifically, in
response to IL-18 in vitro, RA synovial fibroblasts increase their
production of adhesion molecules, intercellular adhesion mol-
ecule 1 (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1), chemokines, IL-8/CXCL8, epithelial neutrophil-
activating peptide 78 (ENA-78/CXCL5), growth-regulated
oncogene-alpha (GROa/CXCL1), stromal cell-derived factor-1
alpha (SDF-1a/CXCL12), monocyte chemotactic protein-1
(MCP-1/CCL2), and macrophage inflammatory protein-3 al-
pha (MIP-3a/CCL20), and an angiogenic mediator vascular
endothelial growth factor (VEGF), all of which are integrally
involved in the pathogenesis of RA. Thus, IL-18 stimulates sy-
novial fibroblasts to release mediators resulting in leukocyte
recruitment and activation as well as new blood vessel forma-
tion. Additionally, IL-18 acts in synergy with IL-12 to stimulate
T cell production of IFN-g, which in turn stimulates synovial
macrophages to produce TNF-a, leading to joint inflammation,
and IL-1b, resulting in cartilage destruction (Fig. 1).
FIG. 1. IL-18 mediates joint
inflammation, cartilage de-
struction, angiogenesis, and
leukocyte recruitment in rheu-
matoid arthritis. IL-18, inter-
leukin-18; IL-12, interleukin-12;
TNF-a, tumor necrosis factor-a;
IFN-g, interferon-g; IL-1b,
interleukin-1b; VEGF, vascular
endothelial growth factor.
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Role of IL-18 in Pathogenesis of Animal Models
of Arthritis
In animal models of arthritis, IL-18 increases inflammation
and cartilage erosion, whereas treatment with IL-18BPa or
anti-IL-18 reduces arthritis, joint erosion, and inflammatory
cytokine expression (Haas and others 2006). Specifically, in
studies using streptococcal cell wall-induced arthritis in
mice, intra-articular injections of anti-IL-18 antibody signifi-
cantly reduced joint swelling and TNF-a and IL-1 levels
( Joosten and others 2000). This reduction in inflammation
and arthritis was independent of IFN-g, as IFN-g gene-
deficient animals with arthritis also responded to the anti-
IL-18 treatment. IL-18 administration to collagen-induced
arthritis (CIA) mice resulted in heightened arthritis and car-
tilage erosion (Gracie and others 1999). IL-18 gene-deficient
mice also have reduced arthritis in various arthritis models,
validating a role for IL-18 in the pathogenesis of RA (Wei
and others 2001). For example, in the zymosan-induced
arthritis model, IL-18 gene-deficient mice, in addition to re-
duced arthritis, showed a reduction in the monocyte che-
moattractant MIP-3a/CCL20, angiogenic mediator VEGF,
and IL-17 (Ruth and others 2010). IL-18 was shown to induce
joint inflammation independent of IL-1 and cartilage de-
struction independent of TNF-a using IL-1 or TNF-a gene-
deficient mice ( Joosten and others 2004). These models
suggest a central role for IL-18 in mediating the joint in-
flammation through initiating inflammatory cytokine pro-
duction, leukocyte extravasation, angiogenesis, and the Th17
autoimmune response.
Synovial Fibroblast Response
to IL-18 Stimulation
Central to the role of IL-18 in the pathogenesis of RA is the
response of the synovial fibroblast to IL-18 stimulation. In vitro
studies by our group and others have shown that IL-18, at
concentrations found in RA synovial fluids, can induce the
production of neutrophil chemoattractants, IL-8/CXCL8,
ENA-78/CXCL5, and GROa/CXCL1 (Morel and others
2001a). This induction of IL-8/CXCL8 was direct, not requir-
ing stimulation with other cytokines such as IL-12, and in-
volved signaling through nuclear factor kappa B (NFkB).
Additionally, IL-18-stimulated RA synovial fibroblasts express
increased levels of adhesion molecules ICAM-1 and VCAM-1
(Morel and others 2001b). This elevation in adhesion molecule
expression by synovial fibroblasts involved IL-18 activation of
multiple signaling pathways (Morel and others 2002). IL-18
induction of RA synovial fibroblast VCAM-1 involved acti-
vation of IRAK/NFkB pathway and Src kinase activation of
both Ras/Raf/ERK/activator protein-1 (AP-1), and phospha-
tidylinositol-3-kinase (PI3K)/Akt pathways (Fig. 2).
IL-18 Mediates Joint Inflammation
IL-18 also mediates joint inflammation by augmenting
leukocyte extravasation through induction of endothelial cell
adhesion molecule expression. In vitro experiments using
human microvascular endothelial cells (HMVECs) showed
that IL-18 stimulation could induce adhesion molecule ex-
pression (Morel and others 2001b). Specifically, IL-18 acti-
vated both NFkB and PI3K signaling pathways resulting in
endothelial cell expression of E-selectin, involved in leuko-
cyte rolling, and ICAM-1 and VCAM-1 involve in leukocyte
firm adhesion. This was verified in experiments showing that
IL-18 treatment of endothelial cells resulted in increased
adhesion of HL-60 cells which was dependent upon leuko-
cyte ligands for E-selectin and ICAM-1 and VCAM-1.
IL-18 is a chemoattractant for synovial CD4+ T lympho-
cytes from patients with RA (Komai-Koma and others 2003).
IL-18 is also important in RA peripheral blood and synovial
fluid neutrophil migration and activation. IL-18R is constitu-
tively expressed on neutrophils and RA synovial fluid neu-
trophils stimulated with IL-18 in vitro produce greater
amounts of chemokines and cytokines (Leung and others
2001). IL-18-induced neutrophil migration is dependent upon
downstream cytokines (TNF-a and Leukotriene B4 [LTB4])
and chemokine (MIP-2/CXCL2 and MIP-1a/CCL3) produc-
tion. This was validated in the mouse CIA model, in which
arthritis was enhanced by IL-18 in part through increased
neutrophil recruitment involving TNF-a and LTB4 (Canetti
and others 2003). Additionally, mature IL-18 is produced by
IL-15-stimulated RA synovial fluid neutrophils but not by
neutrophils from healthy individuals (Verri and others 2007).
The migration of monocytes has also been shown to be
mediated both directly and indirectly by IL-18. Initially, IL-
18 stimulation of RA synovial fibroblasts was shown to
induce the production of monocyte chemoattractant, MIP-3a/
CCL20) (Ruth and others 2003). Subsequently, IL-18 at con-
centrations found in RA synovial fluid was shown to directly
induce both monocyte migration in vitro and in vivo using an
RA synovial tissue severe combined immunodeficiency
(SCID) mouse chimera (Ruth and others 2010). IL-18-induced
migration of monocytes was shown to be dependent upon
signaling through p38 and ERK1/2 pathways (Fig. 2).
TNF-a is an important cytokine in the pathogenesis of RA.
TNF-a is produced by RA synovial macrophages and fibro-
blasts. TNF-a has the ability to induce the production of
IL-18, IL-18BP, and caspase-1 by RA synovial fibroblasts.
Regulation of all 3 of these proteins is necessary to control
the amount of biologically active free IL-18. Recently, the
amount of free IL-18 (biologically active IL-18 not bound by
IL-18BP or soluble IL-18R) was determined to be greater in
RA synovial fluid than in osteoarthritis (OA) synovial fluid
(Shao and others 2009; Marotte and others 2010). This is due
to the paucity of IL-18BP in RA synovial fluid relative to the
amount in OA synovial fluid. Interestingly, activation of the
ERK1/2 signaling pathway is required for the production of
IL-18 by RA synovial fibroblasts; however, it is not involved
in the production of IL-18BP. TNF-a stimulation of RA sy-
novial fibroblasts induces IL-18BPa via activation of c-Jun N
terminal kinase ( JNK) and NFkB, which act upstream of IRF-1
activation (Morotte, unpublished). As a result inhibition of the
ERK1/2 using a specific inhibitor reduces the level of bioactive
IL-18. In vitro treatment of RA synovial fibroblasts with IL-18
does not affect the production of IL-18BP. However, experi-
ments with exogenous IL-18BP-Fc caused a reduction of
ERK1/2 signaling in TNF-a-stimulated RA synovial fibro-
blasts in vitro. This finding suggested that IL-18BPa may be an
important regulator of TNF-a-induced IL-18 expression by RA
synovial fibroblasts and as such is a potential target for future
therapies (Marotte and others 2010).
Angiogenic Properties of IL-18
We initially identified IL-18 as an angiogenic mediator
that can directly induce endothelial cell migration in vitro
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and blood vessel formation in vitro and in vivo (Park and
others 2001; Amin and others 2010). These effects were in-
dependent of other angiogenic mediators, including VEGF,
SDF-1a/CXCL12 or TNF-a, suggesting that IL-18 has direct
angiogenic properties. Accordingly, IL-18 gene-deficient
mice have reduced angiogenesis as determined by the
in vivo Matrigel plug assay (Amin and others 2010). Com-
plicating matters, others have found IL-18 to have anti-
angiogenic properties. Specifically, IL-18 was shown to
inhibit fibroblast growth factor-2 (FGF-2)-induced endothe-
lial cell proliferation in vitro and FGF-induced corneal re-
vascularization in vivo (Cao and others 1999). IL-18 was
also shown to induce cardiac endothelial cell death
(Chandrasekar and others 2006).
FIG. 2. IL-18 initiated signaling pathways in synovial fibroblasts, monocytes, and endothelial cells. ATF-2, activating
transcription factor-2; AP-1, activator protein-1; JNK, c-Jun N terminal kinase; ERK1/2, extracellular signal-regulated kinase
1/2; IKB, inhibitory kappa B (KB); IKK, IKB kinase; IRAK, IL-1 receptor-associated kinase; Jak2, janus kinase; MAPK,
mitogen-activated protein kinase; NFkB, nuclear factor kappa B; NIK, NFkB-inducing kinase; PI3K, phosphatidylinositol-3-
kinase; PKC, protein kinase C; Src, Src kinase; TRAF-6, TNF receptor-associated factor-6.
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RA is a chronic inflammatory disease in which the pro-
liferation and development of blood vessels is critical for
both the development and maintenance of the synovial
pannus. The angiogenic properties of RA synovial tissue
were shown to be in part due to IL-18, as RA synovial tissues
inserted into SCID mouse induced greater HMVEC migra-
tion in response to IL-18 than normal synovial tissue in this
model. Recently, we showed that IL-18-stimulated HMVEC
migration and in vitro tube formation involves Src and JNK
phosphorylation (Amin and others 2010).
Additionally, IL-18 induces RA synovial fibroblasts to
produce angiogenic mediators, including SDF-1a/CXCL12,
MCP-1/CCL2, and VEGF (Cho and others 2006; Amin and
others 2007). RA synovial fibroblasts stimulated with IL-18
signal through p38, NFkB via JNK2 and protein kinase C d
(PKCd), activating transcription factor-2 via JNK2, and Akt
via PI3K to induce SDF-1a (Fig. 2). Similarly, IL-18 stimula-
tion results in MCP-1/CCL2 expression through PI3K acti-
vation of Akt and JNK2 activation of NFkB; however, PKCa,
not PKCd, is involved in NFkB activation. Finally, VEGF ex-
pression in RA synovial fibroblasts was dependent upon IL-
18 stimulation, resulting in either nuclear translocation of
NFkB due to JNK2 and PKCa or activation of the AP-1 sig-
naling pathway (Cho and others 2006; Amin and others 2007).
IL-18 as a Target for Future RA Therapy
The reduction of IL-18 has been an objective of several
treatments for immunological diseases, including RA. Given
the complex regulation of biologically active IL-18, there are
several potential targets that can result in its reduction. Po-
tential tools in reducing IL-18 levels have included IL-18
neutralizing monoclonal antibodies, P2X7 antagonists,
caspase-1 inhibitors, soluble IL-18R, IL-18R blocking mono-
clonal antibodies, IL-18BP, and inhibitors targeting IL-18R
signaling pathways (Fig. 3). In the mouse CIA model, ad-
ministration of either anti-IL-18 or recombinant IL-18BP re-
duced the clinical severity of progressing arthritis through
altering the cytokine balance (Plater-Zyberk and others
2001). Later, a gene therapy approach with adenoviral IL-
18BPc reduced inflammation and joint destruction in mouse
CIA (Smeets and others 2003). Taking this target one step
further, an adenovirus containing IL-18BP and IL-4 fusion
gene was able to alter the immune response in mouse CIA
through increasing Th2 cytokines while, at the same
time, reducing the level of Th1 cytokines (Leng and others
2008). Recombinant human IL-18BP was tried clinically for
the treatment of active moderate to severe RA and has been
reported to be safe at the highest dosage over a 6-week
subcutaneous treatment regiment (Tak and others 2006).
However, therapeutic efficacy of this approach was not
confirmed.
Adenovirus encoding a natural soluble IL-18R b chain
reduced IL-18-induced IFN-g, IL-4, and IL-17 production by
mouse T cells in vitro, suggesting that it functionally inhibits
IL-18 stimulation; however, when administered in vivo in the
mouse CIA model, it exacerbated arthritis and increased the
amount of cartilage and bone erosion (Veenbergen and
others 2010). More promising are caspase-1 inhibitors that in
addition to preventing the conversion of pro-IL-18 to active
mature IL-18 have the added effect of also inhibiting IL-1
activity. A couple of different caspase-1 inhibitors have been
sIL-18R IL-18BPa
IL-18
a
a IL-18
IL-18R
a
b
a IL-18Ra
caspase-1
P2X7 antagonists 
caspase-1 inhibitors
mature IL-18
inactive pro-IL-18
P2X7
signaling inhibitors
FIG. 3. Targets for IL-18-
directed therapy in rheuma-
toid arthritis. a IL-18, anti-IL-18
neutralizing antibody; aIL-
18Ra, anti-IL-18 receptor a;
IL-18BPa, IL-18 binding pro-
tein a; P2X7, purinergic re-
ceptor P2X7; sIL-18R, soluble
IL-18 receptor.
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developed; pralnacasan was the first one to undergo clinical
testing. Phase II clinical trials showed that it significantly
ameliorated RA; however, later trials were stopped due to
liver toxicity problems (Siegmund and Zeitz 2003). Another
specific caspase-1 inhibitor, VX-43198, inhibited the release
of IL-18 from human peripheral blood mononuclear cells
in vitro and its parent molecule V-765 reduced arthritis when
given orally to CIA mice (Wannamaker and others 2007).
Any of these proposed therapies may prove to be a useful
treatment; however, they will need to be specific so as to not
excessively immunosuppress the patient.
Summary
IL-18 is a very potent mediator of inflammation in RA. Its
activity is highly regulated by controlling its expression,
translation, enzymatic cleavage, and release. In addition,
there are both soluble IL-18R and IL-18BP that can bind to
active IL-18 and sequester it preventing its functional activ-
ity. Finally, IL-18-initiated cytoplasmic signaling cascades
are responsible for initiating changes in gene expression and
cell behavior. In the RA joint biologically active IL-18 is
produced by synovial macrophages and synovial fibroblasts
in a positive feedback loop in which TNF-a from synovial
macrophages stimulates synovial fibroblasts to release IL-18,
which in turn stimulates synovial macrophages to release
more TNF-a. In the RA joint, IL-18 induces leukocyte
recruitment through upregulating endothelial adhesion
molecules and by directly functioning as a neutrophil, mac-
rophage, and T lymphocyte chemoattractant and indirectly
by stimulating synovial fibroblasts to release chemokines.
Finally, IL-18 functions as an angiogenic mediator directly
increasing synovial blood vessel formation and indirectly by
inducing synovial fibroblasts to produce angiogenic chemo-
kines and other angiogenic mediators.
Conclusion
Targeting future therapies at regulating IL-18 biological
activity is very promising. The parallels between IL-18 and the
IL-1b activation process make targeting caspase-1 inhibitors
and P2X7 antagonists very attractive because one can poten-
tially inhibit both inflammatory mediators simultaneously.
The naturally occurring IL-18BP and soluble IL-18R are also
prime targets because of their low potential toxicity. Neu-
tralizing anti-IL-18 or anti-IL-18R monoclonal antibodies are
also good potential future therapies as they would have high
affinity for their target antigens. Finally, targeting the signal-
ing pathways that IL-18 activates is a potentially novel ther-
apeutic strategy for the treatment of RA.
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